title: Risks and benefits of antiplatelet therapy in uremic patients.
abstract: Patients with renal insufficiency are at an increased risk for cardiovascular morbidity and mortality. Despite being at a substantial risk for thrombotic events, patients with renal insufficiency also experience a greater number of hemorrhagic complications associated with antiplatelet therapy than individuals with normal renal function. This review focuses on the benefits and risks of antiplatelet therapy in patients with impaired kidney function suffering from an acute coronary syndrome.
authors.affiliation: Duke Heart Center, Department of Medicine, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Washam
authors.forename: George L
authors.initials: GL
authors.lastname: Adams
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D011379:Prognosis; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D014511:Uremia / Q000150:complications* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex